Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations

What is the real-world cost-effectiveness of nirsevimab immunization in preventing respiratory syncytial virus (RSV)–related pediatric hospitalizations?In this multicenter economic evaluation including 5924 RSV-related hospitalizations in 19 pediatric hospitals in Italy, nirsevimab immunization was effective and cost saving in most centers, resulting in negative incremental costs. In 2 centers with later campaign initiation limited to newborns, immunization was less cost-effective with higher costs relative to hospitalizations prevented.These findings suggest that nirsevimab was a cost-saving RSV prevention strategy, highlighting the importance of timely, broad implementation.

Corresponding Author: Federica Attaianese, MD, Pediatric Unit, Meyer Children’s Hospital, Viale Gaetano Pieraccini 24, 50139 Florence, Italy (federica.attaianese@meyer.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.